GHK-CU Specification and Vial Format Review walks through GHK-CU (50mg / 100mg) documentation, vial format, and buyer workflow for Skin & Cosmetic Research laboratories using sulanpeptide.vip.
GHK-CU, also known as Copper Tripeptide-1, is a copper-binding tripeptide complex used in laboratory research on extracellular-matrix signaling, fibroblast models, copper-peptide coordination, and skin-biology research systems.
Scratch wound closure, procollagen type I ELISA, and copper uptake assays by ICP-MS support mechanism studies in cosmetic research laboratories. Loren Pickart’s work established GHK as a plasma peptide fragment with matrix remodeling signatures in gene-expression microarray datasets.
GHK-Cu binds copper(II) to form a tripeptide complex studied for extracellular matrix gene regulation (collagen, elastin, glycosaminoglycan synthesis) in dermal fibroblast cultures. Research measures lysyl oxidase activity and TGF-β pathway transcripts when fibroblasts are treated with copper-peptide complexes at defined concentrations.
Principal investigators should sign off GHK-CU SKUs only after mechanism fit is documented in the study protocol. Spec alignment: Enter exact strength notation (50mg / 100mg) in procurement systems—do not round kit counts.
Side-by-side review of specification table, vial label, and COA prevents release errors for GHK-CU.
Catalog identifiers for GHK-CU: CAS 89030-95-5, Formula: C14H23CuN6O4+. MW 402.92 g/mol, purity target ≥ 99.0%. Copy these fields into requisitions and match them line-by-line on incoming COA PDFs.
Publication methods should list Cat No. and mg strength for GHK-CU to support reproducibility.
Dose planning for GHK-CU should state mass (50mg / 100mg) or molarity derived from catalog molecular weight.
Purity target ≥ 99.0% on the catalog is a specification goal. Release criteria for GHK-CU should state whether the lot COA must meet or exceed that threshold for your Skin & Cosmetic Research assay type. Specification alignment for GHK-CU requires copying exact kit notation (50mg / 100mg) into ERP or LIMS systems. Rounding “10mg×10 vials” to “100mg total” causes mismatches when COA lists per-vial strength and suppliers ship multi-vial kits.
Molecular identifiers for GHK-CU—CAS 89030-95-5, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing GHK-CU should include these fields for reproducibility in Skin & Cosmetic Research journals. Format selection for GHK-CU affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability.
Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for GHK-CU. QA sign-off should reference all four documents in the batch record.
Format selection for GHK-CU affects reconstitution math and aliquot planning. Compare available vial strengths on sulanpeptide.vip against protocol dose ranges before leadership approves a SKU; changing strength mid-study complicates comparability. Side-by-side review of catalog specification table, quote confirmation, vial label, and COA prevents release errors for GHK-CU. QA sign-off should reference all four documents in the batch record.
Molecular identifiers for GHK-CU—CAS 89030-95-5, molecular weight, and formula when listed—should appear on internal sample labels alongside Cat No. Publications citing GHK-CU should include these fields for reproducibility in Skin & Cosmetic Research journals.
GHK-CU from Sulan Peptide Official is for research use only (RUO)—not for human or veterinary use. Questions: Contact page or WhatsApp on sulanpeptide.vip.